胶质母细胞瘤的术后时代：分子生物学如何影响我们的临床管理。综述。
The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.
作者信息
Monticelli M, Zeppa P, Zenga F, Altieri R, Mammi M, Bertero L, Castellano I, Cassoni P, Melcarne A, La Rocca G, Sabatino G, Ducati A, Garbossa D
机构信息
Neurosurgical Unit, Department of Neuroscience, University of Turin, Turin, Italy.
Neurosurgical Unit, Department of Neuroscience, University of Turin, Turin, Italy.
出版信息
Clin Neurol Neurosurg. 2018 Jul;170:120-126. doi: 10.1016/j.clineuro.2018.05.015.
Glioblastoma (GBM) is the most common glioma in adults, with incidence increasing by 3% per year. According to the World Health Organization Classification of Central Nervous System Tumors, GBM is considered a grade IV tumor due to its malignant behavior. The aim of this review is to summarize the main biological aspects of GBM. In particular, we focused our attention on those alterations which have been proven to have an impact on patients' outcome, mainly in terms of overall survival (OS), or on the tumor response to therapies. We have also analyzed the cellular biology and the interactions between GBM and the surrounding environment.
胶质母细胞瘤（GBM）是成人中最常见的胶质瘤，发病率每年以3%的速度增长。根据世界卫生组织中枢神经系统肿瘤分类，GBM因其恶性行为被视为IV级肿瘤。本综述的目的是总结GBM的主要生物学方面。特别是，我们将注意力集中在那些已被证明对患者预后有影响的改变上，主要是在总生存期（OS）方面，或对肿瘤对治疗的反应方面。我们还分析了GBM的细胞生物学以及GBM与周围环境之间的相互作用。
Zotero 插件